Navigation Links
Nottingham-China research collaboration holds hope for bovine and human TB vaccine
Date:4/24/2013

Scientists at The University of Nottingham are studying whether harmful bacteria found in cattle could be harnessed to protect livestock from the devastating disease bovine tuberculosis (TB).

The research, being led by Professor Paul Barrow in the University's School of Veterinary Medicine and Science, could offer an important step towards developing a vaccine against bovine TB, which affects tens of thousands of cattle every year.

The study will investigate the disease in UK and Chinese cattle in collaboration with Professor Xiangmei Zhou at Beijing's China Agricultural University. The two-year project has been funded with a 200,000 grant from the Research Councils UK (RCUK) and Chinese Ministry of Science and Technology (MoST) China-UK Cooperation Programme in Global Priorities.

Professor Barrow said: "We have discovered very interesting and novel interactions between different bacterial types during mixed infections. One bacterial type can stimulate short term immunity against unrelated bacteria providing a degree of protection. We want to look to see if a similar relationship occurs between the bovine tubercle bascillus and other bacteria which are present in the tissues at the same time."

Bovine TB is a bacterial disease that in 2011 resulted in the slaughter of approximately 25,000 cattle in England at a cost of more than 90 million. Recent figures released by Defra show that the slaughter of cows increased by 10 per cent in 2012, with more than 38,000 animals being destroyed. In an effort to control the disease, the Government has introduced the bovine TB eradication programme including the proposed cull of badgers which have been found to be carriers of the disease.

In China, bovine TB is now a major economic problem, causing hardship for farmers and their families living in rural communities. In any one herd, up to 70 per cent of cattle can be affected.

Bovine TB is also a zoonosis an infectious disease that can cross the species barrier to spread from animal to human. In the UK, early detection means the disease is never allowed to reach the point where it can threaten human health. However, in China some spread of the bacterium which is the origin of the disease, Mycobacterium bovis, does result in some human tuberculosis. TB is a chronic disease that eats away at the lungs over a long period of time, eventually leading to breathing difficulties. Effective treatment can take up to two years, which is not a practical or financial option for impoverished people often living in remote locations.

The Nottingham scientists will be investigating whether being infected by other related bacteria could offer a protective effect against bovine TB. In particular, they are looking at another common cattle bacterium called Mycobacterium paratuberculosis, which causes the gut wasting condition Johne's Disease and has been tentatively linked with Crohn's disease in humans.

The researchers will be using advanced microarray technology to test samples from cattle from both the UK and China to detect the mixture of bacteria that may be present in a single animal. Colleagues in China will be conducting in vitro assays in cell culture to study whether the presence of one bacterium may affect the immune system in response to another.

The research could potentially lead to the development of an emergency vaccine that could be used to stimulate rapid resistance to bovine TB in the event that infection is found within a herd. Similarly, the application could also apply to humans, with family members being vaccinated quickly after the diagnosis of TB in a close relative.

Professor Wang Tao, Vice-President of the China Agricultural University said: "China Agricultural University and University of Nottingham signed a Memorandum of Understanding in 2011. Since then, the two universities have paid frequent visits to each other to promote a proposal of strategic partnership.

"Last year, both sides invested seed funding to encourage joint research in the three key areas of veterinary medicine, food security and biomass. We are excited to see a positive step forward that the young scientists of both universities have made in the platform.

"As one of the projects sponsored by CAU-UoN seed funding, this is the first achievement in concrete collaboration between the two universities. I believe it will lead our future into more productive cooperation in research, teaching and faculty & student exchange."

Professor Hai-Sui Yu, Pro-Vice-Chancellor (International) at The University of Nottingham, said: "We regard our partnership with CAU as a strategic one as such significant internal funding from The University of Nottingham has been used to pump-priming world-class research collaborations with CAU. I'm delighted that one of the projects that we supported internally has secured prestigious external funding."


'/>"/>

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-011-595-15793
University of Nottingham
Source:Eurekalert

Related medicine news :

1. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
2. NIH awards $20 million over 5 years to train next generation of global health researchers
3. Researchers develop a new cell and animal model of inflammatory breast cancer
4. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
5. Sexually abused boys at risk for more unsafe sex: UBC research
6. Researchers Find Gene Mutations That May Be a Key to Autism
7. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
8. Researchers find evidence of banned antibiotics in poultry products
9. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
10. Scientific session and new research highlights
11. NJ stroke researchers report advances in spatial neglect research at AAN Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” hits ... proof that attitude and determination can combine into the most remarkable achievements. Over ... holidays. This campaign will offer patients a new-found hope, by seizing the opportunity ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic imaging ... Heart at their tradeshow booth # 941 for the American Association of Equine ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016 Lianluo Smart Limited ... "the Company") which develops, markets and sells medical ... China and international markets, recently ... and Treatment New Progress Forum, co-hosted by the ... Province , Guangdong Provincial People,s Hospital and ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
Breaking Medicine Technology: